Disease relevance of Dyspareunia

• Complications of ovarian transposition were present in four patients: intestinal occlusion, dyspareunia, functional ovarian cysts, and pelvic adhesions with tubal obstruction [1].
• RESULTS: Buserelin acetate markedly reduced dysmenorrhea, pelvic pain, and dyspareunia during the treatment and also for the 12 subsequent months [2].
• Estrogen deficient women are prone to problems such as vaginal dryness, dyspareunia and a predilection to recurrent urinary tract infections and urinary incontinence [3].
• Further trials are needed, however, to verify whether the good results observed are maintained during an entire 5-year period, to confirm the efficacy on dyspareunia and dyschezia, and to compare the effects of the levonorgestrel intrauterine device with those of other treatment options [4].
• Estrogen replacement therapy in conjunction with a progestin regimen not only controls hot flashes, osteoporosis, dyspareunia, and other estrogen-deficiency symptoms, but also prevents the potential risk of estrogen treatment such as endometrial and/or breast carcinoma and cardiovascular disorders [5].

Psychiatry related information on Dyspareunia

• This article describes an integrated treatment, where adjunctive sildenafil use was an important strategic component in the sex therapy of a couple's unconsummated marriage in which the wife's vaginismus, dyspareunia, and anorgasmia was complicated by her husband's ED and retarded ejaculation (RE) [6].

High impact information on Dyspareunia

• The therapy (combined contraceptive pill and estrogen cream) had a marked effect on urogenital symptoms (vaginal dryness, dyspareunia, urinary frequency, and urinary urgency), with impressive improvement comparably in both groups [7].
• During tamoxifen the most frequent complaints were hot flushes (85%), disturbed sleep (55%), vaginal dryness and/or dyspareunia (47%), decreased sexual desire (44%) and musculo-skeletal symptoms (43%) [8].
• Women treated with tibolone report significant reductions in vaginal dryness and dyspareunia, effects that may be secondary to both estrogenic and androgenic actions [9].
• RESULTS: At 6 months of treatment, a significant reduction in deep dyspareunia was observed in both groups, with goserelin superior to the OC at linear analog scale assessment [10].
• Both dyspareunia and chronic pain were significantly reduced by the gestrinone treatment [11].

Chemical compound and disease context of Dyspareunia

• Sildenafil seems to improve arousal, orgasm and sexual enjoyment, and dyspareunia in women affected by type 1 diabetes [12].
• The 41 women with no identifiable laparoscopic abnormality did not differ significantly from the 95 with pelvic abnormalities in respect of age, parity, duration of pain, frequency of dysmenorrhoea and dyspareunia or the presence of gastro-intestinal or urinary symptoms [13].
• Women allocated polyglactin 910 were less likely to have dyspareunia (8% versus 13%; RR 0.59, 95% CI 0.39 to 0.91; 2P = 0.02) and less likely to fail to resume pain-free intercourse (8% versus 14%; RR 0.57, 95% CI 0.38 to 0.87; 2P < 0.01) [14].
• CONCLUSION: Topical nitroglycerin is safe and effective in providing temporary relief of introital dyspareunia and vulvar pain in women with vulvodynia [15].
• Hormonal therapy with danazol or with leuprolide resulted in reduction of symptoms but was associated with amenorrhea in both cases and with dyspareunia in the second patient [16].

Biological context of Dyspareunia

• Certain types of estrogen therapy were associated with increased frequency of sexual activity, enjoyment, desire, arousal, fantasies, satisfaction, vaginal lubrication, and feeling physically attractive, and reduced dyspareunia, vaginal dryness, and sexual problems [17].

Gene context of Dyspareunia

• Musculoskeletal pain and dyspareunia significantly increased under first-line non-steroidal aromatase inhibitors (p=0.0039 and p=0.001, respectively), while patients under tamoxifen had significant decrease in sexual interest (p< or =0.0001) [18].

References